XML 45 R28.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaborative Arrangements and Licensing Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
AstraZeneca [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with AstraZeneca |  | $ | 129,759 |  |  | $ | 202,236 |  |  | $ | 79,160 |
Percentage of total revenue |  |  | 18 | % |  |  | 26 | % |  |  | 13 | %
Biogen [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with Biogen (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with Biogen |  | $ | 368,058 |  |  | $ | 350,146 |  |  | $ | 366,696 |
Percentage of total revenue |  |  | 52 | % |  |  | 44 | % |  |  | 62 | %
GSK [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with GSK (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with GSK |  | $ | — |  |  | $ | 15,000 |  |  | $ | — |
Percentage of total revenue |  |  | 0 | % |  |  | 2 | % |  |  | 0 | %
Novartis [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with Novartis (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with Novartis |  | $ | 37,762 |  |  | $ | 30,194 |  |  | $ | 237 |
Percentage of total revenue |  |  | 5 | % |  |  | 4 | % |  | Less than 1% |
Roche [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with Roche (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with Roche |  | $ | 39,871 |  |  | $ | 48,838 |  |  | $ | 67,202 |
Percentage of total revenue |  |  | 6 | % |  |  | 6 | % |  |  | 11 | %
Otsuka [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the year ended December 31, 2024, we earned the following revenue from our relationship with Otsuka (in thousands, except percentage amount):
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |
Revenue from our relationship with Otsuka |  | $ | 46,856 |  |  | $ | 56,480 |
Percentage of total revenue |  |  | 7 | % |  |  | 7 | %
Alnylam [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the years ended December 31, 2024, 2023 and 2022, we earned the following revenue from our relationship with Alnylam (in thousands, except percentage amounts):
|  | Year Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with Alnylam |  | $ | 8,110 |  |  | $ | 28,426 |  |  | $ | 21,389 |
Percentage of total revenue |  |  | 1 | % |  |  | 4 | % |  |  | 4 | %

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstrazenecaCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_GlaxoSmithKlineCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_NovartisCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_RocheCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_OtsukaCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AlnylamPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |